200 related articles for article (PubMed ID: 23287988)
1. A Phase-1b study of tivantinib (ARQ 197) in adult patients with hepatocellular carcinoma and cirrhosis.
Santoro A; Simonelli M; Rodriguez-Lope C; Zucali P; Camacho LH; Granito A; Senzer N; Rimassa L; Abbadessa G; Schwartz B; Lamar M; Savage RE; Bruix J
Br J Cancer; 2013 Jan; 108(1):21-4. PubMed ID: 23287988
[TBL] [Abstract][Full Text] [Related]
2. Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study.
Rimassa L; Assenat E; Peck-Radosavljevic M; Pracht M; Zagonel V; Mathurin P; Rota Caremoli E; Porta C; Daniele B; Bolondi L; Mazzaferro V; Harris W; Damjanov N; Pastorelli D; Reig M; Knox J; Negri F; Trojan J; López López C; Personeni N; Decaens T; Dupuy M; Sieghart W; Abbadessa G; Schwartz B; Lamar M; Goldberg T; Shuster D; Santoro A; Bruix J
Lancet Oncol; 2018 May; 19(5):682-693. PubMed ID: 29625879
[TBL] [Abstract][Full Text] [Related]
3. Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study.
Santoro A; Rimassa L; Borbath I; Daniele B; Salvagni S; Van Laethem JL; Van Vlierberghe H; Trojan J; Kolligs FT; Weiss A; Miles S; Gasbarrini A; Lencioni M; Cicalese L; Sherman M; Gridelli C; Buggisch P; Gerken G; Schmid RM; Boni C; Personeni N; Hassoun Z; Abbadessa G; Schwartz B; Von Roemeling R; Lamar ME; Chen Y; Porta C
Lancet Oncol; 2013 Jan; 14(1):55-63. PubMed ID: 23182627
[TBL] [Abstract][Full Text] [Related]
4. Selective Inhibitor of the c-Met Receptor Tyrosine Kinase in Advanced Hepatocellular Carcinoma: No Beneficial Effect With the Use of Tivantinib?
Zhao S; Wu W; Jiang H; Ma L; Pan C; Jin C; Mo J; Wang L; Wang K
Front Immunol; 2021; 12():731527. PubMed ID: 34804015
[TBL] [Abstract][Full Text] [Related]
5. Tivantinib in hepatocellular carcinoma.
Trojan J; Zeuzem S
Expert Opin Investig Drugs; 2013 Jan; 22(1):141-7. PubMed ID: 23167786
[TBL] [Abstract][Full Text] [Related]
6. Phase I study of tivantinib in Japanese patients with advanced hepatocellular carcinoma: Distinctive pharmacokinetic profiles from other solid tumors.
Okusaka T; Aramaki T; Inaba Y; Nakamura S; Morimoto M; Moriguchi M; Sato T; Ikawa Y; Ikeda M; Furuse J
Cancer Sci; 2015 May; 106(5):611-7. PubMed ID: 25711511
[TBL] [Abstract][Full Text] [Related]
7. Tivantinib: critical review with a focus on hepatocellular carcinoma.
Rota Caremoli E; Labianca R
Expert Opin Investig Drugs; 2014 Nov; 23(11):1563-74. PubMed ID: 25307444
[TBL] [Abstract][Full Text] [Related]
8. A phase I study of tivantinib in combination with temsirolimus in patients with advanced solid tumors.
Kyriakopoulos CE; Braden AM; Kolesar JM; Eickhoff JC; Bailey HH; Heideman J; Liu G; Wisinski KB
Invest New Drugs; 2017 Jun; 35(3):290-297. PubMed ID: 28004284
[TBL] [Abstract][Full Text] [Related]
9. Phase 1 dose-escalation trial evaluating the combination of the selective MET (mesenchymal-epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib.
Goldman JW; Laux I; Chai F; Savage RE; Ferrari D; Garmey EG; Just RG; Rosen LS
Cancer; 2012 Dec; 118(23):5903-11. PubMed ID: 22605616
[TBL] [Abstract][Full Text] [Related]
10. Tivantinib: a new promising mesenchymal-epithelial transition factor inhibitor in the treatment of hepatocellular carcinoma.
Rimassa L; Personeni N; Simonelli M; Santoro A
Future Oncol; 2013 Feb; 9(2):153-65. PubMed ID: 23414466
[TBL] [Abstract][Full Text] [Related]
11. A phase I dose-escalation study of Tivantinib (ARQ 197) in adult patients with metastatic solid tumors.
Rosen LS; Senzer N; Mekhail T; Ganapathi R; Chai F; Savage RE; Waghorne C; Abbadessa G; Schwartz B; Dreicer R
Clin Cancer Res; 2011 Dec; 17(24):7754-64. PubMed ID: 21976535
[TBL] [Abstract][Full Text] [Related]
12. Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor-associated tumors: results of a multicenter phase 2 trial.
Wagner AJ; Goldberg JM; Dubois SG; Choy E; Rosen L; Pappo A; Geller J; Judson I; Hogg D; Senzer N; Davis IJ; Chai F; Waghorne C; Schwartz B; Demetri GD
Cancer; 2012 Dec; 118(23):5894-902. PubMed ID: 22605650
[TBL] [Abstract][Full Text] [Related]
13. Tivantinib (ARQ197) in hepatocellular carcinoma.
Porta C; Giglione P; Ferrari A; Reversi F; Liguigli W; Imarisio I; Ganini C
Expert Rev Anticancer Ther; 2015 Jun; 15(6):615-22. PubMed ID: 26035719
[TBL] [Abstract][Full Text] [Related]
14. A randomized, double-blind, placebo-controlled, phase 3 study of tivantinib in Japanese patients with MET-high hepatocellular carcinoma.
Kudo M; Morimoto M; Moriguchi M; Izumi N; Takayama T; Yoshiji H; Hino K; Oikawa T; Chiba T; Motomura K; Kato J; Yasuchika K; Ido A; Sato T; Nakashima D; Ueshima K; Ikeda M; Okusaka T; Tamura K; Furuse J
Cancer Sci; 2020 Oct; 111(10):3759-3769. PubMed ID: 32716114
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of tivantinib (ARQ 197) in patients with metastatic triple-negative breast cancer.
Tolaney SM; Tan S; Guo H; Barry W; Van Allen E; Wagle N; Brock J; Larrabee K; Paweletz C; Ivanova E; Janne P; Overmoyer B; Wright JJ; Shapiro GI; Winer EP; Krop IE
Invest New Drugs; 2015 Oct; 33(5):1108-14. PubMed ID: 26123926
[TBL] [Abstract][Full Text] [Related]
16. A phase 2 multicenter study of tivantinib (ARQ 197) monotherapy in patients with relapsed or refractory germ cell tumors.
Feldman DR; Einhorn LH; Quinn DI; Loriot Y; Joffe JK; Vaughn DJ; Fléchon A; Hajdenberg J; Halim AB; Zahir H; Motzer RJ
Invest New Drugs; 2013 Aug; 31(4):1016-22. PubMed ID: 23417696
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of the c-MET inhibitor tivantinib (ARQ 197) in patients with relapsed or relapsed/refractory multiple myeloma.
Baljevic M; Zaman S; Baladandayuthapani V; Lin YH; de Partovi CM; Berkova Z; Amini B; Thomas SK; Shah JJ; Weber DM; Fu M; Cleeland CS; Wang XS; Stellrecht CM; Davis RE; Gandhi V; Orlowski RZ
Ann Hematol; 2017 Jun; 96(6):977-985. PubMed ID: 28337527
[TBL] [Abstract][Full Text] [Related]
18. A phase II trial of a selective c-Met inhibitor tivantinib (ARQ 197) monotherapy as a second- or third-line therapy in the patients with metastatic gastric cancer.
Kang YK; Muro K; Ryu MH; Yasui H; Nishina T; Ryoo BY; Kamiya Y; Akinaga S; Boku N
Invest New Drugs; 2014 Apr; 32(2):355-61. PubMed ID: 24337769
[TBL] [Abstract][Full Text] [Related]
19. A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-Met inhibitor tivantinib (ARQ 197) in Asian patients with previously treated stage IIIB/IV nonsquamous nonsmall-cell lung cancer harboring wild-type epidermal growth factor receptor (ATTENTION study).
Yoshioka H; Azuma K; Yamamoto N; Takahashi T; Nishio M; Katakami N; Ahn MJ; Hirashima T; Maemondo M; Kim SW; Kurosaki M; Akinaga S; Park K; Tsai CM; Tamura T; Mitsudomi T; Nakagawa K
Ann Oncol; 2015 Oct; 26(10):2066-72. PubMed ID: 26153496
[TBL] [Abstract][Full Text] [Related]
20. Tivantinib for the treatment of hepatocellular carcinoma.
Best J; Schotten C; Lohmann G; Gerken G; Dechêne A
Expert Opin Pharmacother; 2017 May; 18(7):727-733. PubMed ID: 28414564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
